Those who suffer from Alzheimer’s disease in Puerto Rico will soon be able to use a cannabis-based treatment to treat the condition, thanks to a new medicine that will be available in the country.
According to a press release, the new experimental treatment called Hyalolex is a cannabis-based medicine aimed at helping with things like agitation, anxiety and sleep disorder in patients. “We are very pleased to work with the DaMa Pharmaceutical team to bring Hyalolex to Puerto Rico, which has a long history of developing premier pharmaceutical products,” stated Ram Mukunda, CEO of India Globalization Capital, Inc. “We are proud to be a contributor to Puerto Rico’s economic development and to the well-being of its Alzheimer’s patients. This is a decisive step in delivering our cannabis intellectual property to patients, after many years of development. It is particularly important as part of our effort to establish a distribution network to productize our IP.”
This experimental treatment is being offered in Puerto Rico because people of Latin origin are about one-and-a-half times as likely to be diagnosed with Alzheimer’s disease as white or non-Latin people. Because so many people suffer from Alzheimer’s disease later in life, this is an important chance to study its positive effects. The press release also states that more than 5.3 million Americans suffer from Alzheimer’s disease, and 65 percent of diagnosed patients are female.
Puerto Rico residents have already made a lot of positive cannabis decisions, from local cannabis advocacy groups helping with hurricane relief to the launch of their medical cannabis program which was a major step for medical legalization. It appears that the country is on track to be one of the leaders in the industry. Hyalolex is estimated to arrive on shelves sometime this month, and will be available in 10 of the 30 dispensaries currently operating in Puerto Rico.